What does this research mean for the field?

Question

Accepted Answer

Recombinant human interleukin 1 receptor antagonist (rhIL-1ra) does not significantly improve overall survival in patients with sepsis syndrome or shock, though secondary analyses suggest potential dose-related survival benefits in subgroups with organ dysfunction or high baseline mortality risk. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

Discussion

Member takes

Overview

Key Points

Cite This Study